Citigroup’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-107,481
| Closed | -$171K | – | 5872 |
|
|
2024
Q1 | $171K | Buy |
107,481
+100,093
| +1,355% | +$148K | ﹤0.01% | 4088 |
|
|
2023
Q4 | $6.35K | Buy |
7,388
+6,333
| +600% | +$5.56K | ﹤0.01% | 5291 |
|
|
2023
Q3 | $1.13K | Sell |
1,055
-14,894
| -93% | -$30.8K | ﹤0.01% | 5080 |
|
|
2023
Q2 | $41.3K | Buy |
15,949
+14,235
| +831% | +$50.8K | ﹤0.01% | 4741 |
|
|
2023
Q1 | $6.99K | Sell |
1,714
-429
| -20% | -$1.98K | ﹤0.01% | 4855 |
|
|
2022
Q4 | $10.8K | Sell |
2,143
-8,015
| -79% | -$50.2K | ﹤0.01% | 4814 |
|
|
2022
Q3 | $133K | Sell |
10,158
-2,758
| -21% | -$41.8K | ﹤0.01% | 3964 |
|
|
2022
Q2 | $165K | Buy |
12,916
+2,477
| +24% | +$34.3K | ﹤0.01% | 3958 |
|
|
2022
Q1 | $159K | Sell |
10,439
-6,799
| -39% | -$106K | ﹤0.01% | 4199 |
|
|
2021
Q4 | $305K | Sell |
17,238
-220,589
| -93% | -$4.23M | ﹤0.01% | 4109 |
|
|
2021
Q3 | $5M | Buy |
237,827
+137,509
| +137% | +$3.03M | ﹤0.01% | 1835 |
|
|
2021
Q2 | $1.98M | Buy |
100,318
+95,997
| +2,222% | +$2.25M | ﹤0.01% | 2679 |
|
|
2021
Q1 | $125K | Sell |
4,321
-3,020
| -41% | -$84.5K | ﹤0.01% | 4258 |
|
|
2020
Q4 | $222K | Buy |
7,341
+2,125
| +41% | +$46.5K | ﹤0.01% | 4911 |
|
|
2020
Q3 | $83K | Sell |
5,216
-2,116
| -29% | -$38.6K | ﹤0.01% | 5260 |
|
|
2020
Q2 | $145K | Sell |
7,332
-3,842
| -34% | -$73.4K | ﹤0.01% | 5271 |
|
|
2020
Q1 | $138K | Buy |
11,174
+1,128
| +11% | +$18.4K | ﹤0.01% | 5064 |
|
|
2019
Q4 | $186K | Buy |
10,046
+9,716
| +2,944% | +$142K | ﹤0.01% | 5251 |
|
|
2019
Q3 | $4K | Sell |
330
-1,545
| -82% | -$23.2K | ﹤0.01% | 7415 |
|
|
2019
Q2 | $27K | Buy |
+1,875
| New | +$27.4K | ﹤0.01% | 6936 |
|
Citigroup's NGM Position: Q2 2024 in Review
Citigroup sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 107,481 shares — an estimated $171K sold.
Citigroup first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $5M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Citigroup reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Citigroup sold 107,481 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $171K.
- Citigroup first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Citigroup's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $5M in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.